CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Align Technology Q3 revenue slightly beats estimates

By Reuters News


Overview

  • US clear aligner maker's Q3 revenue grew yr/yr, a slight beat of analyst expectations

  • Adjusted EPS for Q3 beat analyst expectations

  • Company repurchased about 627,000 shares in Q3, plans up to $300 mln buyback in Q4


Outlook

  • Align sees Q426 worldwide revenue between $1.0 bln and $1.02 bln

  • Company expects 2026 Clear Aligner volume and revenue growth up 5% to 6% year-over-year


Result Drivers

  • CLEAR ALIGNER VOLUME - Co said growth was driven by record doctor submitters, higher shipments, improved utilization, and broad-based international growth

  • EXPENSE MANAGEMENT - Co attributed improved operating margin to disciplined expense management and productivity improvements

  • SCANNER PLACEMENTS - Co said double-digit growth in iTero scanner placements contributed to performance


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Slight Beat*

$1.01 bln

$1.005 bln (12 Analysts)

Q3 Adjusted EPS

Beat

$2.80

$2.78 (14 Analysts)

Q3 EPS

$1.90

Q3 Adjusted Net Income

Slight Beat*

$198.90 mln

$198.21 mln (11 Analysts)

Q3 Net Income

$135 mln

Q3 Adjusted Operating Margin

24.40%

Q3 Gross Profit

$697.47 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 9 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Align Technology, Inc. is $197.39, about 29.9% above its October 27 closing price of $151.95

  • The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 14 three months ago


Reuters Recommended Reads

  • Oct 28 - Boston Scientific warns of tough 2027 on China pricing, heart-device weakness

  • Oct 28 - Straumann sees North America stabilising, China demand improving after Q3 beat

  • Oct 28 - Boston Scientific Q3 revenue beats estimates despite cybersecurity disruption


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.